![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Roche’s Tecentriq Gets FDA Priority Review for Advanced Non-Small Cell Lung Cancer
Roche’s Tecentriq Gets FDA Priority Review for Advanced Non-Small Cell Lung Cancer
The FDA granted Roche’s Tecentriq priority review (atezolizumab) as a first-line monotherapy for patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type).
The supplemental BLA is based on results from a phase 3 clinical trial, which showed that Tecentriq monotherapy improved overall survival compared with chemotherapy in patients with high PD-L1 expression (TC3/IC3-WT).
Tecentriq is currently approved for treating various forms of non-small cell and small cell lung cancer, PD-L1-positive metastatic triple-negative breast cancer, and certain types of metastatic urothelial cancer.
Upcoming Events
-
18Jul
-
21Oct